Treatment adherence remains a central challenge in opioid use disorder management, with discontinuation rates reflecting both systemic barriers and individual-level obstacles.1,2 Daily oral medication regimens, while effective, require consistent engagement with pharmacies, stable housing, and organizational capacity that may be compromised during active addiction or recovery transitions.2
The pharmacological mechanism underlying buprenorphine efficacy, partial mu-opioid receptor agonism with high binding affinity and slow dissociation, remains consistent across formulations, yet delivery method often impacts real-world treatment outcomes and treatment satisfaction.2,3 Patients experiencing homelessness, involvement with criminal justice systems, or psychosocially complex life circumstances may struggle to maintain daily medication routines, leading to treatment interruptions and elevated relapse risk.2,4
Long-acting injectable buprenorphine formulations aim to address these adherence challenges through extended pharmacokinetic profiles.3,5 Weekly and monthly injectable preparations eliminate daily decision-making around medication administration while providing steady-state plasma concentrations. Extended pharmacokinetic profiles offer theoretical adherence advantage for populations with prior difficulties maintaining daily regimens, though robust comparative effectiveness evidence across formulations remains limited.5
Critical transition points including emergency department discharge, release from incarceration, and hospital departure, represent high-risk periods for treatment discontinuation and overdose.4-6 Notably, individuals referred to OUD treatment through the criminal justice system remain significantly less likely to receive medications for OUD (MOUD) compared to those referred through other sources, underscoring the urgency of addressing this gap at these critical junctures.4
Women frequently describe treatment obstacles that extend beyond the clinical setting.1 Caregiving demands, worry about how treatment participation affects their children, limited access to reliable childcare, and competing household responsibilities can make sustained engagement in recovery difficult. In this context, prioritizing their own health may feel secondary to immediate family needs.
Longer-acting formulations may help maintain therapeutic continuity during periods where daily adherence or frequent pharmacy visits are impractical. Fewer in-person pickups may also reduce stigma-related stress and ease scheduling pressures for those navigating work, transportation challenges, and primary caregiving roles.
Clinicians managing OUD across diverse clinical settings should consider how medication delivery method aligns with individual patient circumstances, recognizing that optimal adherence support varies based on social determinants, treatment history, and recovery stage.6
Take our opioid use disorder quiz to see how your knowledge compares to your peers.
